Preliminary results of a clinical trial of 4-phenylbutyrate (PBA) “show a significant reduction in seizure activity among participants.”

Approximately 1% of the U.S. population — 2 million to 3 million adults — experience critical illness requiring the placement of a breathing tube each year.

VUMC researchers tested a treatment combining immunotherapy and online adaptive radiotherapy, which is tailored to real-time tumor changes during the treatment plan.

Researchers examined if childhood obesity could be prevented by leveraging a combination of health behavior counseling offered by pediatric primary care clinicians and modern digital health literacy tools.

The study, a randomized and controlled clinical trial, tested the effectiveness of montelukast in 1,250 outpatients with acute post-COVID-19 symptoms.

The therapy, P-BCMA-ALL01, demonstrated a 91% overall response rate for the 23 patients participating in the phase 1 trial.

Two hundred study participants were assessed for oxidative stress, acute kidney injury, delirium, myocardial injury and atrial fibrillation.